Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
id1 shrna
- Development stage
- Preclinical
- Lead developer
- H. Lee Moffitt Cancer Center & Research Institute
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intratumoral
01
Overview
Id1 shRNA is a short hairpin RNA (shRNA) construct designed to silence the expression of the Inhibitor of DNA Binding 1 (ID1) protein through RNA interference (RNAi). ID1 is a helix-loop-helix transcription factor often overexpressed in various malignancies, including pancreatic adenocarcinoma, glioblastoma, and hepatocellular carcinoma, where it promotes tumor proliferation, invasion, and chemoresistance. In research settings, Id1 shRNA is typically delivered via lentiviral vectors to create stable knockdown cell lines for studying the Src-dependent signaling axis and its role in tumorigenesis. While it has shown efficacy in reducing tumor burden and restoring gemcitabine sensitivity in preclinical mouse models, it is primarily utilized as a research reagent rather than a clinical-stage therapeutic.
- Other names
- Id1 shRNAId-1 shRNAId 1 shRNAID1 short hairpin RNAID-1 short hairpin RNAID 1 short hairpin RNAshRNA-Id1shRNA-Id-1shRNA-Id 1sh-Id1sh-Id-1sh-Id 1
02
Targets
ID1 (DNA-binding protein inhibitor ID-1 (ID1) mRNA)
Beyond the preview
Go deeper on id1 shrna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on id1 shrna.